These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies. Fabrizi F; Dixit V; Messa P; Martin P J Viral Hepat; 2014 Oct; 21(10):681-9. PubMed ID: 25040244 [TBL] [Abstract][Full Text] [Related]
7. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407 [TBL] [Abstract][Full Text] [Related]
8. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Carriero D; Fabrizi F; Uriel AJ; Park J; Martin P; Dieterich DT Int J Artif Organs; 2008 Apr; 31(4):295-302. PubMed ID: 18432584 [TBL] [Abstract][Full Text] [Related]
9. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients. Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122 [TBL] [Abstract][Full Text] [Related]
10. Recent advances on hepatitis C virus in dialysis population. Fabrizi F; Messa P; Martin P Kidney Blood Press Res; 2014; 39(4):260-71. PubMed ID: 25171295 [TBL] [Abstract][Full Text] [Related]
11. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Gurusamy KS; Tsochatzis E; Toon CD; Davidson BR; Burroughs AK Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006573. PubMed ID: 24297303 [TBL] [Abstract][Full Text] [Related]
12. Aminoadamantanes for chronic hepatitis C. Lamers MH; Broekman M; Drenth JP; Gluud C Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C and Its Metabolic Complications in Kidney Disease. Fabrizi F; Donato FM; Messa P Ann Hepatol; 2017 November-December,; 16(6):851-861. PubMed ID: 29055921 [TBL] [Abstract][Full Text] [Related]
14. Management of hepatitis C in HIV infected and other immunocompromised individuals. Seth AK Trop Gastroenterol; 2006; 27(3):111-7. PubMed ID: 17310553 [TBL] [Abstract][Full Text] [Related]
15. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. Lamers MH; Broekman M; Drenth JP; Gluud C Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404 [TBL] [Abstract][Full Text] [Related]
16. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? Fabrizi F; Dixit V; Messa P J Viral Hepat; 2012 Sep; 19(9):601-7. PubMed ID: 22863263 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus infection and the dialysis patient. Fabrizi F; Lunghi G; Ganeshan SV; Martin P; Messa P Semin Dial; 2007; 20(5):416-22. PubMed ID: 17897248 [TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience. Alsaran K; Sabry A; Shaheen N Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669 [TBL] [Abstract][Full Text] [Related]
19. [The management of dialysis patients seropositive for HBsAg, anti-HCV, or anti-HIV antibodies]. Fabrizi F; Messa P G Ital Nefrol; 2012; 29 Suppl 56():S78-84. PubMed ID: 23059944 [TBL] [Abstract][Full Text] [Related]
20. Pegylated Interferon Mono-Therapy of Chronic Hepatitis C in the Dialysis Population: Systematic Review and Meta-Analysis. Fabrizi F; Dixit V; Messa P; Martin P Ther Apher Dial; 2015 Dec; 19(6):611-21. PubMed ID: 26197927 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]